ISTA Pharmaceuticals releases preliminary results from phase II/III study of bepotastine

May 8, 2007

ISTA Pharmaceuticals Inc. announced results from the preliminary analysis of its phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily.